Dr Nimesh Patel

Profile

Nimesh Patel is Reader (Associate Professor) in Medical Education. He leads on all assessment activity within the School of Medicine, Institute of Health Sciences Education. His oversight for assessments primarily covers the 5-year MBBS programme (London and Malta campus), 4-year MBBS graduate entry programme and 2-year MSc Physician Associate Studies.

Nimesh completed his BSc (Hons) in Pharmacology with Extra Mural Year in 2001 at King’s College London. During his Extra Mural Year he spent 16 months in the lab of Prof Christoph Thiemermann at the William Harvey Research Institute, Queen Mary University of London. He returned to the William Harvey Research Institute to complete his PhD in acute renal failure in 2005.

He continued as a post-doctoral researcher at the William Harvey Research Institute and was awarded a 3-year career development fellowship in 2011 from Kidney Research UK.

In 2013, Nimesh took on the role of Head of Student Selected Components for the MBBS followed by the Head of Assessments in 2014 and appointed as Senior Lecturer.

He was elected to the Medical Schools Council Assessment Advisory Board in 2018 where he has supported work looking at exam security, reasonable adjustments for exams, and the UK Medical Licencing Assessment (MLA). In 2022 he was appointed to the Medical Schools Council Applied Knowledge Test MLA Exam Board.

Click here to book a meeting with Nimesh Patel

Teaching

Nimesh is currently module lead for Assessment, Evaluation, Curriculum and Quality (IHS6013) on the intercalated BSc Medical Education course. He facilitates PBLs in years 1 and 2 of the MBBS and supports MBBS students as a MedPro supervisor. He has also acted as an SSC supervisor for various years of the MBBS programme.

Research

Research Interests:

Nimesh has interests in understanding the differential outcomes of students across the MBBS.

Publications

1. Blythe J, Patel NSA, Spiring W, Easton G, Evans D, Meskevicius-Sadler E, Noshib H, Gordon H. Undertaking a high stakes virtual OSCE ("VOSCE") during Covid-19. BMC Med Educ. 2021 Apr 20;21(1):221.
2. Kozato A, Patel N, Shikino K. A randomised controlled pilot trial of the influence of non-native English accents on examiners' scores in OSCEs. BMC Med Educ. 2020 Aug 15;20(1):268.
3. Bangash MN, Abbott TEF, Patel NSA, Hinds CJ, Thiemermann C, Pearse RM. The Effect of β₂ Adrenoceptor Agonists on Leucocyte-Endothelial Adhesion in a Rodent Model of Laparotomy and Endotoxemia. Front Immunol. 2020 May 21;11:1001.
4. Voisin MB, Leoni G, Woodfin A, Loumagne L, Patel NS, Di Paola R, Cuzzocrea S, Thiemermann C, Perretti M, Nourshargh S. Neutrophil elastase plays a non-redundant role in remodeling the venular basement membrane and neutrophil diapedesis post-ischemia/reperfusion injury. J Pathol. 2019 May;248(1):88-102.
5. Yuzugulen J, Douthwaite JA, Wood EG, Villar IC, Patel NSA, Jegard J, Gaertner H, Rossitto-Borlat I, Rose K, Hartley O, Cutillas PR, Ahluwalia A, Corder R. Characterisation of preproendothelin-1 derived peptides identifies Endothelin-Like Domain Peptide as a modulator of Endothelin-1. Sci Rep. 2017 Jul 10;7(1):4956.
6. Johnson FL, Patel NSA, Purvis GSD, Chiazza F, Chen J, Sordi R, Hache G, Merezhko VV, Collino M, Yaqoob MM, Thiemermann C. Inhibition of IκB Kinase at 24 Hours After Acute Kidney Injury Improves Recovery of Renal Function and Attenuates Fibrosis. J Am Heart Assoc. 2017 Jul 3;6(7):e005092.
7. Sordi R, Nandra KK, Chiazza F, Johnson FL, Cabrera CP, Torrance HD, Yamada N, Patel NS, Barnes MR, Brohi K, Collino M, Thiemermann C. Artesunate Protects Against the Organ Injury and Dysfunction Induced by Severe Hemorrhage and Resuscitation. Ann Surg. 2017 Feb;265(2):408-417.
8. Chen J, Kieswich JE, Chiazza F, Moyes AJ, Gobbetti T, Purvis GS, Salvatori DC, Patel NS, Perretti M, Hobbs AJ, Collino M, Yaqoob MM, Thiemermann C. IκB Kinase Inhibitor Attenuates Sepsis-Induced Cardiac Dysfunction in CKD. J Am Soc Nephrol. 2017 Jan;28(1):94-105.
9. Madalli S, Beyrau M, Whiteford J, Duchene J, Singh Nandhra I, Patel NS, Motwani MP, Gilroy DW, Thiemermann C, Nourshargh S, Scotland RS. Sex-specific regulation of chemokine Cxcl5/6 controls neutrophil recruitment and tissue injury in acute inflammatory states. Biol Sex Differ. 2015 Nov 26;6:27.
10. Sordi R, Chiazza F, Johnson FL, Patel NS, Brohi K, Collino M, Thiemermann C. Inhibition of IκB Kinase Attenuates the Organ Injury and Dysfunction Associated with Hemorrhagic Shock. Mol Med. 2015 Jun 18;21(1):563-75.
11. Sordi R, Chiazza F, Patel NS, Doyle RA, Collino M, Thiemermann C. 'Preconditioning' with low dose lipopolysaccharide aggravates the organ injury / dysfunction caused by hemorrhagic shock in rats. PLoS One. 2015 Apr 1;10(4):e0122096.
12. Chen J, Chiazza F, Collino M, Patel NS, Coldewey SM, Thiemermann C. Gender dimorphism of the cardiac dysfunction in murine sepsis: signalling mechanisms and age-dependency. PLoS One. 2014 Jun 19;9(6):e100631.
13. Coldewey SM, Rogazzo M, Collino M, Patel NS, Thiemermann C. Inhibition of IκB kinase reduces the multiple organ dysfunction caused by sepsis in the mouse. Dis Model Mech. 2013 Jul;6(4):1031-42.
14. Coldewey SM, Khan AI, Kapoor A, Collino M, Rogazzo M, Brines M, Cerami A, Hall P, Sheaff M, Kieswich JE, Yaqoob MM, Patel NS, Thiemermann C. Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor. Kidney Int. 2013 Sep;84(3):482-90.
15. Bangash MN, Patel NS, Benetti E, Collino M, Hinds CJ, Thiemermann C, Pearse RM. Dopexamine can attenuate the inflammatory response and protect against organ injury in the absence of significant effects on hemodynamics or regional microvascular flow. Crit Care. 2013 Mar 28;17(2):R57.
16. Khan AI, Coldewey SM, Patel NS, Rogazzo M, Collino M, Yaqoob MM, Radermacher P, Kapoor A, Thiemermann C. Erythropoietin attenuates cardiac dysfunction in experimental sepsis in mice via activation of the β-common receptor. Dis Model Mech. 2013 Jul;6(4):1021-30.
17. Nandra KK, Collino M, Rogazzo M, Fantozzi R, Patel NS, Thiemermann C. Pharmacological preconditioning with erythropoietin attenuates the organ injury and dysfunction induced in a rat model of hemorrhagic shock. Dis Model Mech. 2013 May;6(3):701-9.
18. Patel NS, Kerr-Peterson HL, Brines M, Collino M, Rogazzo M, Fantozzi R, Wood EG, Johnson FL, Yaqoob MM, Cerami A, Thiemermann C. Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury. Mol Med. 2012 May 9;18(1):719-27.
19. Nandra KK, Takahashi K, Collino M, Benetti E, Wong WS, Goh FY, Suzuki K, Patel NS, Thiemermann C. Acute treatment with bone marrow-derived mononuclear cells attenuates the organ injury/dysfunction induced by hemorrhagic shock in the rat. Shock. 2012 Jun;37(6):592-8.
20. Patel NS, Nandra KK, Brines M, Collino M, Wong WF, Kapoor A, Benetti E, Goh FY, Fantozzi R, Cerami A, Thiemermann C. A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock. Mol Med. 2011 Sep- Oct;17(9-10):883-92.
21. Kapoor A, Shintani Y, Collino M, Osuchowski MF, Busch D, Patel NS, Sepodes B, Castiglia S, Fantozzi R, Bishop-Bailey D, Mota-Filipe H, Yaqoob MM, Suzuki K, Bahrami S, Desvergne B, Mitchell JA, Thiemermann C. Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock. Am J Respir Crit Care Med. 2010 Dec 15;182(12):1506-15.
22. Maio R, Sepodes B, Patel NS, Thiemermann C, Mota-Filipe H, Costa P. Erythropoietin preserves the integrity and quality of organs for transplantation after cardiac death. Shock. 2011 Feb;35(2):126-33.
23. Milsom AB, Patel NS, Mazzon E, Tripatara P, Storey A, Mota-Filipe H, Sepodes B, Webb AJ, Cuzzocrea S, Hobbs AJ, Thiemermann C, Ahluwalia A. Role for endothelial nitric oxide synthase in nitrite-induced protection against renal ischemia-reperfusion injury in mice. Nitric Oxide. 2010 Feb 15;22(2):141-8.
24. Kumar S, Allen DA, Kieswich JE, Patel NS, Harwood S, Mazzon E, Cuzzocrea S, Raftery MJ, Thiemermann C, Yaqoob MM. Dexamethasone ameliorates renal ischemia- reperfusion injury. J Am Soc Nephrol. 2009 Nov;20(11):2412-25.
25. Scheiermann C, Colom B, Meda P, Patel NS, Voisin MB, Marrelli A, Woodfin A, Pitzalis C, Thiemermann C, Aurrand-Lions M, Imhof BA, Nourshargh S. Junctional adhesion molecule-C mediates leukocyte infiltration in response to ischemia reperfusion injury. Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1509-15.
26. Tripatara P, Patel NS, Brancaleone V, Renshaw D, Rocha J, Sepodes B, Mota- Filipe H, Perretti M, Thiemermann C. Characterisation of cystathionine gamma- lyase/hydrogen sulphide pathway in ischaemia/reperfusion injury of the mouse kidney: an in vivo study. Eur J Pharmacol. 2009 Mar 15;606(1-3):205-9.
27. Patel NS, di Paola R, Mazzon E, Britti D, Thiemermann C, Cuzzocrea S. Peroxisome proliferator-activated receptor-alpha contributes to the resolution of inflammation after renal ischemia/reperfusion injury. J Pharmacol Exp Ther. 2009 Feb;328(2):635-43.
28. Tripatara P, Patel NS, Collino M, Gallicchio M, Kieswich J, Castiglia S, Benetti E, Stewart KN, Brown PA, Yaqoob MM, Fantozzi R, Thiemermann C. Generation of endogenous hydrogen sulfide by cystathionine gamma-lyase limits renal ischemia/reperfusion injury and dysfunction. Lab Invest. 2008 Oct;88(10):1038-48.
29. Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10925-30.
30. Patel NS, Cuzzocrea S, Collino M, Chaterjee PK, Mazzon E, Britti D, Yaqoob MM, Thiemermann C. The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo. Eur J Pharmacol. 2007 May 7;562(1-2):148-54.
31. Tripatara P, Patel NS, Webb A, Rathod K, Lecomte FM, Mazzon E, Cuzzocrea S, Yaqoob MM, Ahluwalia A, Thiemermann C. Nitrite-derived nitric oxide protects the rat kidney against ischemia/reperfusion injury in vivo: role for xanthine oxidoreductase. J Am Soc Nephrol. 2007 Feb;18(2):570-80.
32. Cuzzocrea S, Di Paola R, Mazzon E, Patel NS, Genovese T, Muià C, Crisafulli C, Caputi AP, Thiemermann C. Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med. 2006 Apr;34(4):1168-77.
33. Dugo L, Collin M, Allen DA, Patel NS, Bauer I, Mervaala EM, Louhelainen M, Foster SJ, Yaqoob MM, Thiemermann C. GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med. 2005 Sep;33(9):1903-12.
34. Collino M, Patel NS, Lawrence KM, Collin M, Latchman DS, Yaqoob MM, Thiemermann C. The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int. 2005 Aug;68(2):529-36.
35. Cuzzocrea S, Mazzon E, di Paola R, Genovese T, Patel NS, Britti D, de Majo M, Caputi AP, Thiemermann C. Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse. Arthritis Rheum. 2005 Mar;52(3):940-50.
36. Patel NS, Cortes U, Di Poala R, Mazzon E, Mota-Filipe H, Cuzzocrea S, Wang ZQ, Thiemermann C. Mice lacking the 110-kD isoform of poly(ADP-ribose) glycohydrolase are protected against renal ischemia/reperfusion injury. J Am Soc Nephrol. 2005 Mar;16(3):712-9.
37. Abdelrahman M, Mazzon E, Bauer M, Bauer I, Delbosc S, Cristol JP, Patel NS, Cuzzocrea S, Thiemermann C. Inhibitors of NADPH oxidase reduce the organ injury in hemorrhagic shock. Shock. 2005 Feb;23(2):107-14.
38. Di Paola R, Mazzon E, Patel NS, Genovese T, Muià C, Thiemermann C, De Sarro A, Cuzzocrea S. Beneficial effects of GW274150 treatment on the development of experimental colitis induced by dinitrobenzene sulfonic acid. Eur J Pharmacol. 2005 Jan 10;507(1-3):281-9.
39. Cuzzocrea S, Mazzon E, Di Paola R, Genovese T, Patel NS, Muià C, Threadgill MD, De Sarro A, Thiemermann C. 5-Aminoisoquinolinone reduces colon injury by experimental colitis. Naunyn Schmiedebergs Arch Pharmacol. 2004 Dec;370(6):464-73.
40. Patel NS, Chatterjee PK, Di Paola R, Mazzon E, Britti D, De Sarro A, Cuzzocrea S, Thiemermann C. Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J Pharmacol Exp Ther. 2005 Mar;312(3):1170-8.
41. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Caputi AP, Thiemermann C. Tempol reduces the activation of nuclear factor-kappaB in acute inflammation. Free Radic Res. 2004 Aug;38(8):813-9.
42. Pétrilli V, Herceg Z, Hassa PO, Patel NS, Di Paola R, Cortes U, Dugo L, Filipe HM, Thiemermann C, Hottiger MO, Cuzzocrea S, Wang ZQ. Noncleavable poly(ADP-ribose) polymerase-1 regulates the inflammation response in mice. J Clin Invest. 2004 Oct;114(8):1072-81.
43. Genovese T, Mazzon E, Muià C, Patel NS, Threadgill MD, Bramanti P, De Sarro A, Thiemermann C, Cuzzocrea S. Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma. J Pharmacol Exp Ther. 2005 Feb;312(2):449-57.
44. Collin M, Rossi A, Cuzzocrea S, Patel NS, Di Paola R, Hadley J, Collino M, Sautebin L, Thiemermann C. Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. J Leukoc Biol. 2004 Nov;76(5):961-70.
45. Patel NS, Sharples EJ, Cuzzocrea S, Chatterjee PK, Britti D, Yaqoob MM, Thiemermann C. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int. 2004 Sep;66(3):983-9.
46. Cuzzocrea S, Mazzon E, Di Paola R, Patel NS, Genovese T, Muià C, De Sarro A, Thiemermann C. Erythropoietin reduces the development of experimental inflammatory bowel disease. J Pharmacol Exp Ther. 2004 Dec;311(3):1272-80.
47. Patel NS, Collin M, Thiemermann C. Urocortin does not reduce the renal injury and dysfunction caused by experimental ischaemia/reperfusion. Eur J Pharmacol. 2004 Aug 2;496(1-3):175-80.
48. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia- reperfusion. J Am Soc Nephrol. 2004 Aug;15(8):2115-24.
49. Patel NS, Cuzzocrea S, Chatterjee PK, Di Paola R, Sautebin L, Britti D, Thiemermann C. Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. Mol Pharmacol. 2004 Aug;66(2):220-7.
50. Abdelrahman M, Sharples EJ, McDonald MC, Collin M, Patel NS, Yaqoob MM, Thiemermann C. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock. 2004 Jul;22(1):63-9.
51. Cuzzocrea S, Dugo L, Patel NS, Di Paola R, Cockerill GW, Genovese T, Thiemermann C. High-density lipoproteins reduce the intestinal damage associated with ischemia/reperfusion and colitis. Shock. 2004 Apr;21(4):342-51.
52. Collin M, Patel NS, Dugo L, Thiemermann C. Role of peroxisome proliferator-activated receptor-gamma in the protection afforded by 15-deoxydelta12,14 prostaglandin J2 against the multiple organ failure caused by endotoxin. Crit Care Med. 2004 Mar;32(3):826-31.
53. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Britti D, Patel NS, Di Paola R, Genovese T, Di Rosa M, Caputi AP, Thiemermann C. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute pancreatitis induced by cerulein. Intensive Care Med. 2004 May;30(5):951-6.
54. Chatterjee PK, Patel NS, Cuzzocrea S, Brown PA, Stewart KN, Mota-Filipe H, Britti D, Eberhardt W, Pfeilschifter J, Thiemermann C. The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J2 ameliorates ischemic acute renal failure. Cardiovasc Res. 2004 Feb 15;61(3):630-43.
55. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Di Paola R, Genovese T, Chatterjee PK, Fulia F, Cuzzocrea E, Di Rosa M, Caputi AP, Thiemermann C. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med. 2004 Feb;32(2):457-66.
56. Chatterjee PK, Patel NS, Kvale EO, Brown PA, Stewart KN, Mota-Filipe H, Sharpe MA, Di Paola R, Cuzzocrea S, Thiemermann C. EUK-134 reduces renal dysfunction and injury caused by oxidative and nitrosative stress of the kidney. Am J Nephrol. 2004 Mar-Apr;24(2):165-77.
57. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Maffia P, Patel NS, Di Paola R, Ialenti A, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol. 2004 Jan 1;483(1):79-93.
58. Cuzzocrea S, Mazzon E, Dugo L, Patel NS, Serraino I, Di Paola R, Genovese T, Britti D, De Maio M, Caputi AP, Thiemermann C. Reduction in the evolution of murine type II collagen induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. Arthritis Rheum. 2003 Dec;48(12):3544-56.
59. Chatterjee PK, Patel NS, Kvale EO, Brown PA, Stewart KN, Britti D, Cuzzocrea S, Mota-Filipe H, Thiemermann C. The tyrosine kinase inhibitor tyrphostin AG126 reduces renal ischemia/reperfusion injury in the rat. Kidney Int. 2003 Nov;64(5):1605-19.
60. Chatterjee PK, Kvale EO, Patel NS, Thiemermann C. GW274150 inhibits nitric oxide production by primary cultures of rat proximal tubular cells. Med Sci Monit. 2003 Oct;9(10):BR357-62.
61. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Di Paola R, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut. Br J Pharmacol. 2003 Sep;140(2):366-76.
62. Cuzzocrea S, Rossi A, Pisano B, Di Paola R, Genovese T, Patel NS, Cuzzocrea E, Ianaro A, Sautebin L, Fulia F, Chatterjee PK, Caputi AP, Thiemermann C. Pyrrolidine dithiocarbamate attenuates the development of organ failure induced by zymosan in mice. Intensive Care Med. 2003 Nov;29(11):2016-25.
63. Sivarajah A, Chatterjee PK, Patel NS, Todorovic Z, Hattori Y, Brown PA, Stewart KN, Mota-Filipe H, Cuzzocrea S, Thiemermann C. Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol. 2003 Jul-Aug;23(4):267-76.
64. Thiemermann C, Patel NS, Kvale EO, Cockerill GW, Brown PA, Stewart KN, Cuzzocrea S, Britti D, Mota-Filipe H, Chatterjee PK. High density lipoprotein (HDL) reduces renal ischemia/reperfusion injury. J Am Soc Nephrol. 2003 Jul;14(7):1833-43.
65. Chatterjee PK, Patel NS, Sivarajah A, Kvale EO, Dugo L, Cuzzocrea S, Brown PA, Stewart KN, Mota-Filipe H, Britti D, Yaqoob MM, Thiemermann C. GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int. 2003 Mar;63(3):853-65.
66. Patel NS, Chatterjee PK, Chatterjee BE, Cuzzocrea S, Serraino I, Brown PA, Stewart KN, Mota-Filipe H, Thiemermann C. TEMPONE reduces renal dysfunction and injury mediated by oxidative stress of the rat kidney. Free Radic Biol Med. 2002 Dec 1;33(11):1575-89.
67. Chatterjee PK, Patel NS, Kvale EO, Cuzzocrea S, Brown PA, Stewart KN, Mota-Filipe H, Thiemermann C. Inhibition of inducible nitric oxide synthase reduces renal ischemia/reperfusion injury. Kidney Int. 2002 Mar;61(3):862-71

Reviews

1. Blythe J, Eden T, MacAninch E, Buckner L, Martyn K, Ray S, Patel N, Fernandes K. Case studies and realist review of nutrition education innovations within the UK medical undergraduate curricula. BMJ Nutrition, Prevention & Health 2022 Nov 7;5(2):352-357
2. Benetti E, Chiazza F, Patel NSA, Collino M. The NLRP3 Inflammasome as a novel player of the intercellular crosstalk in metabolic disorders. Mediators Inflamm. 2013;2013:678627
3. Patel NSA, Nandra KK, Thiemermann C. Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care. Crit Care. 2012 Jul 26;16(4):229
4. Patel NSA, Collino M, Yaqoob MM, Thiemermann C. Erythropoietin in the intensive care unit – beyond treatment of anemia. Ann Intensive Care. 1:40, 2011.
5. Benetti E, Patel NSA, Collino M. The role of PPARβ/δ in the management of metabolic syndrome and its associated cardiovascular complications. Endocr Metab Immune Disord Drug Targets. 2011 Dec;11(4):273-84
6. Collino M, Patel NSA, Thiemermann C. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. Ther Adv Cardiovasc Dis. 2008 Jun;2(3):179-97